Compliance In Focus

Our annual report announcing the Top 5 Warning Letter Findings for Clinical Investigators for 2012 is hot off the press! Take the time to download and read IMARC’s newest whitepaper “2012 Top 5” list. This list is not intended to point fingers at investigators, but rather, to document the non-compliance trends in an effort to raise industry awareness of improvement needed. Whether you are a sponsor, a monitor, or an investigative site, everyone has a stake in the outcome of an FDA BIMO inspection.

We call it providing a "Third Set of Eyes."  Interestingly enough, most IMARC monitors have a background in nursing, or as research coordinators. It may very well be that this experience has assisted us in monitoring to empathize with each subject. After all, so many years were spent one-on-one with patients; we see them as individuals- not just subject numbers.